Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114, United States
Location status: Recruiting
NCT Number: NCT04735263
interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT
Interested in participating?
Request Info50 year–85 year
All sexes
Interventional
Phase 2
Boston, Massachusetts, 02114, United States
Location status: Recruiting
Dark adaptation recovery time is a sensitive marker of AMD progression in intermediate AMD, largely owing to drusen volume providing a transport barrier that slows the transfer of nutrients between the choroid and photoreceptors2. Consequently, dark adaptation may provide an early indication of response vs. nonresponse, aiding case-by-case decisions on continuation of treatment when patients experience adverse side effects (e.g., elevated CPK or liver enzymes) or when atorvastatin provides insufficient lipid control in patients also at high-risk for cardiovascular disease (and switching to an alternative statin might be desirable).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
High-risk iAMD (numerous large, confluent drusen covering ≥ 0.5 disk area, with or without pigmentary changes but having no evidence of GA or CNV) in the study eye
Subjects can have either:
(i) Bilateral high-risk iAMD, or (ii) High-risk iAMD in one eye with GA and/or CNV in the fellow eye.
Exclusion criteria
Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
Other names: Lipitor 80 mg(Brand name)
Time frame: 18 Months
Determine weather improvement in dark adaptation recovery time or rod intercept time (RIT) can be used as an early indicator of positive response to high dose statin therapy for intermediate AMD patients
Time frame: 18 months
To measure and quantify improvement or positive response to high dose statin therapy in patients with intermediate AMD using drusen volume measured by SDOCT
Time frame: 18 months
Patient will have Dark Adaptation testing performed to check change in vision function with changes in drusen volume.
Time frame: 18 months
Patient will have Best Corrected visual acuity, testing performed to check changes in vision function
Time frame: 18 months
Patient will have quantitative contrast sensitivity function testing performed to check change in vision function with changes in drusen volume.
Time frame: 18 months
Patient will have microperimetry function testing performed to check change in this vision function with changes in drusen volume
Contact information is provided by the study sponsor or research team.
Deeba Husain
CONTACT
John B Miller, MD
CONTACT
Massachusetts Eye and Ear Infirmary
Other
Acronym: DELPHI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07440225
Age-Related Macular Degeneration, Choroid Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT07496567
Age-Related Macular Degeneration, Choroid Diseases
Gilbert, Arizona, United States
View Trial DetailsNCT06662162
Age-Related Macular Degeneration, Age-Related Macular Degeneration (ARMD)
Manchester, Connecticut, United States
View Trial DetailsNCT06237127
Age-Related Macular Degeneration, Eye Diseases
Sacramento, California, United States
View Trial Details